FOR AGENT/BROKER USE ONLY. DO NOT DISTRIBUTE.
Evernorth GeneFocus
A new oncology genetic testing solution for identifying inherited cancer risk earlier with accessible genetic testing, provider guidance, and personalized prevention strategies.
Helping members understand risk earlier—and act sooner
Evernorth® GeneFocus, with the first focus being oncology-centered, helps members identify inherited cancer risk before cancer develops or earlier in the disease journey. By pairing genetic insight with education and support, the program enables more informed decisions around prevention, screening, and long‑term health.
What the solution does:
Provides access to hereditary cancer risk genetic testing
Helps identify members with inherited cancer risk who may not qualify under standard testing guidelines
Complements existing medical and pharmacy oncology benefits, including Evernorth Oncology Benefit Services℠
How Evernorth GeneFocus works
The client joins for a per-member-per-month and fee-for-service fee.
A member receives clear, easy-to-understand education and chooses whether to pursue genetic testing.
The member connects with their provider who orders the genetic test.
The test is completed at-home or at a LabCorp® location.
Results are reviewed and explained with guidance on next steps such as screening, prevention, or lifestyle changes.
Why this matters for clients
Reduce
Reduce avoidable high‑cost cancer events
Improve
Improve treatment effectiveness through earlier intervention
Support
Support better use of health care dollars over time
Strengthen
Strengthen a long‑term, sustainable oncology strategy
Why this matters for members
With personalized genetic insight, members can:
Begin screening earlier or more frequently, when appropriate
Take steps to reduce future cancer risk
Make more informed health decisions with provider guidance
Avoid unnecessary or ineffective care
Looking ahead
The solution is designed to grow over time, with future enhancements planned across pharmacogenomics, residual disease testing, and tumor profiling—supporting even more personalized oncology care.
Key date and client action:
July 1, 2026: Oncology genetic testing solution becomes available
Client action: No immediate action required today; consultants can begin positioning the solution with clients focused on prevention‑oriented oncology strategies and long‑term cost management